NAD Injections and NAD+ Injections: What the Mechanism Actually Tells You (And What It Doesn't)

NAD injections are a method of delivering nicotinamide adenine dinucleotide — the coenzyme your cells use to run energy production, DNA repair, and a class of enzymes called sirtuins — directly into the body. You'll see the term written as "NAD injections" and "NAD+ injections" interchangeably; the "+" refers to the oxidized, active form of the molecule, and that's what's being administered.

What makes the injection route different from oral NAD supplements (NMN, NR, nicotinamide): injections bypass the enzymatic conversion steps your gut and liver have to complete before a precursor becomes usable NAD+. You're delivering the finished molecule — not a raw material and a prayer that the machinery converts it efficiently.

Two main injection formats exist: subcutaneous (SubQ — into the fatty tissue just under the skin) and intramuscular (IM — into muscle tissue). Both are distinct from IV NAD+ infusions, which deliver directly into the bloodstream over several hours in a clinical setting. The differences between these routes — speed of absorption, side-effect profile, and practicality — matter more than most guides acknowledge. More on that below.

At Protocol MD, NAD+ injections are physician-prescribed, compounded at a licensed 503A pharmacy, and dosed based on your specific labs and clinical picture. Not a supplement. Not a wellness shot. A prescription.

NAD+ is not a nutrient in the vitamin sense. It's a coenzyme — a molecule that proteins need in order to do their jobs. Think of it as the molecule that shuttles electrons through the mitochondrial machinery that produces ATP. No NAD+, no electron transport chain. No electron transport chain, no ATP. No ATP, no cell. The cascade doesn't get more fundamental than that.

But NAD+ isn't just a passive carrier. It's also the substrate — the raw material — for two enzyme families that have become the center of serious aging research.

Sirtuins are a family of seven proteins (SIRT1 through SIRT7) that regulate everything from inflammatory signaling to mitochondrial biogenesis to DNA repair. They're NAD+-dependent — every deacetylation reaction they run consumes one NAD+ molecule. When NAD+ is abundant, sirtuins are active. When it's depleted — which increasingly describes the aging cell — they aren't. SIRT1 handles stress response and mitochondrial function. SIRT3 localizes to the mitochondria and fine-tunes the enzymes of the electron transport chain itself. SIRT6 works on chromatin and is involved in telomere maintenance and DNA damage signaling.

PARP-1 is the cell's primary DNA-damage sensor. When a strand breaks, PARP-1 tags the site with ADP-ribose polymers — repair-crew markings — and each ADP-ribose unit costs one NAD+ molecule. A cell under high DNA-damage load (which is what "chronic oxidative stress" means in practice) runs a sustained PARP-1 response, drawing down NAD+, which in turn suppresses sirtuin activity, which impairs mitochondrial function, which generates more oxidative stress. It's a loop, and it's not a pleasant one.

Then there's CD38 — arguably the least glamorous actor in this story and possibly the most important one for understanding why NAD declines with age. CD38 is an enzyme on immune cells that hydrolyzes NAD+ for its own signaling purposes. Unlike sirtuins and PARP, it doesn't recycle what it uses — it's a consumer in the pure sense. CD38 expression is driven up by chronic low-grade inflammation: IL-6, TNF-alpha, IFN-gamma — the cytokine cocktail that tends to accumulate with age, the one researchers have started calling "inflammaging." Data from mouse models showed that CD38-knockout animals don't experience the NAD+ decline that wild-type animals show with age. That's not a human trial. But it is a plausible mechanism for why NAD falls as reliably as it does — not just because synthesis slows down, but because inflammatory demand goes up.

One more piece: NAMPT (nicotinamide phosphoribosyltransferase) is the rate-limiting enzyme in the salvage pathway — the primary route by which your cells recycle NAD+ precursors back into usable NAD+. NAMPT activity declines with age and is suppressed by some of the same inflammatory signals that upregulate CD38. This matters because it means the aging cell faces a double problem: increased consumption and reduced recycling efficiency. Oral precursors like NMN and NR depend on this salvage machinery to convert to NAD+. If NAMPT is already compromised, that conversion is less efficient than it looks in a healthy young adult.

The honest answer is: meaningfully, and across multiple tissues, over the adult lifespan. The specific percentage varies by tissue, by measurement method, and by individual — so anyone floating a precise universal number is rounding aggressively. What the research describes is a substantial decline between early adulthood and later decades, driven by the compounding pressure of increased consumption (more DNA damage, more inflammatory signaling, upregulated CD38) against a synthesis pathway that becomes less efficient with age.

There's no standard NAD blood panel that tells you you're "low" — no equivalent of a ferritin draw or a 25-OH vitamin D. What there is, is a growing body of mechanistic evidence explaining why the decline matters and a pharmacological question about the most efficient way to address it.

Interest in NAD therapies has surged by nearly 400% over the past five years as that evidence base has grown. That's not a clinical outcome. It's a signal that the mechanism is resonating with people who've looked at the biochemistry and decided it's worth their attention.

The question "what does NAD injections do" is the right one to start with, because the honest answer is more nuanced than most guides admit. Here's what the mechanism supports — and where the human evidence is thin.

What NAD injections are doing at the cellular level:

NAD injections replenish intracellular NAD+ levels, which in theory does three things simultaneously: (1) reactivates sirtuin-dependent pathways for mitochondrial function and stress response, (2) restores PARP-1's ability to run DNA damage repair without immediately depleting the rest of the cell's NAD+ pool, and (3) reduces the demand-deficit gap caused by CD38 and declining NAMPT activity.

What people report noticing:

• Improved energy and reduced fatigue (the most consistently reported early effect — mechanistically plausible, since mitochondrial function directly determines cellular energy output)
• Improved cognitive clarity ("brain fog" reduction) — plausible given SIRT1 and SIRT3 expression in neurons and the brain's disproportionate energy demand
• Faster exercise recovery — consistent with mitochondrial biogenesis and DNA repair pathways running more efficiently
• Improved sleep quality — associated with NAD+'s role in circadian rhythm signaling via SIRT1

What the evidence actually says:

One pilot study found fatigue improvement following a single nicotinamide riboside dose in older men. That's preliminary. A 2018 study in Nature Communications confirmed oral NR raises blood NAD+ levels in healthy middle-aged adults, with real but modest and variable effects. The mechanistic basis is solid. Large, controlled human trials with clinical endpoints for injectable NAD+ specifically — particularly for longevity — don't yet exist.

The honest framing: NAD injections address a real biochemical mechanism. The reported effects are consistent with that mechanism. The human evidence, particularly at longevity endpoints, is still catching up. Anyone presenting this as settled science is overclaiming, and this audience will notice.

This is where most guides oversimplify. There are three meaningfully different approaches, and the distinctions matter.

Oral supplements: NMN and NR (the "pills")

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the most heavily studied approaches. The logic is sound: your cells convert these precursors into NAD+ via established enzymatic pathways. A 2018 study in Nature Communications confirmed that oral NR in healthy middle-aged and older adults produced statistically significant increases in blood NAD+ levels. The effect was real. It was also modest and variable across individuals — which is the part that gets left out of the supplement-industry citation.

The variability is the key word. Conversion efficiency through NAMPT and related enzymes isn't constant — it varies by tissue, by age, and presumably by individual genetics. You're not directly controlling how much NAD+ ends up inside the cells that need it most; you're hoping the conversion machinery runs efficiently enough to get you there.

For younger, metabolically healthy adults with good NAMPT activity, oral precursors may be sufficient. For older adults with compromised salvage pathway function, the efficiency gap is more relevant. NAD injections vs pills comes down to bioavailability and conversion dependency — injections remove one variable that matters more as the salvage pathway declines.

IV NAD+ infusions

One pilot study found that a continuous infusion of NAD+ produced a 398% increase in plasma NAD+ levels after six hours. That's the ceiling of what NAD+ delivery can look like, administered in a clinical setting over several hours.

IV infusions deliver directly to circulation with no absorption variables. The trade-off: clinic visits, infusion time (typically three to four hours for loading doses), and cost per session that runs higher than injections. Rate-dependent sensations — flushing, mild chest tightness, nausea — are common at higher infusion speeds; these are manageable by slowing the rate, but they make rapid high-dose IV administration uncomfortable in a way subcutaneous delivery avoids.

Subcutaneous NAD injections

Subcutaneous administration delivers NAD+ into the tissue just under the skin. You get direct delivery without the conversion dependency of oral precursors and without the clinic time, rate-sensitivity, and per-session cost of IV. Absorption is slower than IV — this is a feature, not a bug, for ongoing maintenance dosing where steady systemic availability matters more than peak plasma concentration.

Whether subcutaneous delivery produces superior intracellular NAD+ enrichment compared to oral precursors, in well-controlled human trials, is a genuine gap in the evidence. The pharmacokinetic argument is compelling. The direct clinical comparison between routes — in humans, at a rigorous level — is still thin. We're accurate about that.

You'll see NAD+ sold three ways, and the difference is the delivery route, not the molecule. NMN and NR are oral precursors — raw ingredients your body has to absorb and convert into NAD+. Injectable and IV NAD+ deliver it more directly, bypassing digestion, which is why many patients find injectable forms more noticeable. There's also a regulatory wrinkle worth knowing: as of late 2022, the FDA no longer permits NMN to be sold as a dietary supplement in the US, which leaves much of the oral-NMN market in a gray area. Physician-prescribed, 503A-compounded injectable NAD+ is the direct, regulated route — the middle path between a supplement and a costly clinic IV.

For the full precursor-vs-direct breakdown, see NMN vs NAD+.

People searching "how to inject NAD" are usually asking one of two questions: what does the process involve, or can I do this at home? The short answers are "less complicated than you'd think" and "with the right prescription and training, yes" — but the order of operations matters.

This section covers administration routes at an educational level only. Dosing, technique, and whether any route is appropriate for you is determined by your prescribing physician — not this blog.

Subcutaneous (SubQ) injection

The most common approach for at-home NAD injection protocols. A small-gauge needle delivers the solution into the subcutaneous fat — typically the abdomen, outer thigh, or back of the upper arm. The same sites you'd use for insulin or a GLP-1 pen. Absorption into systemic circulation happens gradually over minutes to hours; this produces a more sustained NAD+ availability curve than IV without the clinic setting requirement.

Technique matters: sterile preparation, proper site rotation to avoid localized irritation, and correct angle and depth. These are things a provider walks you through before you go home with a kit. The mechanics are not complicated — subcutaneous injection is one of the most routine self-administration procedures in medicine. The prescription is the gate.

Intramuscular (IM) injection

IM delivers into muscle tissue — typically the deltoid or vastus lateralis. Absorption is generally faster than SubQ. Some protocols use IM; others prefer SubQ for ease of self-administration. Which is appropriate depends on the prescribed formulation and your provider's determination.

What "home administration" actually means

At Protocol MD: after your intake, labs, and physician review, if a SubQ protocol is prescribed, you receive the compounded NAD+ from a 503A pharmacy with proper labeling, concentration, and sterility, and a physician who has reviewed your history. Training on self-injection technique is part of the protocol handoff. You are not improvising with an unlabeled vial from a website. That distinction is the whole argument.

"Before and after" for NAD injections is a legitimate search — people want to know what actually changes and over what timeline. The compliance note here is straightforward: we cannot make or imply outcome guarantees, and anyone who shows you dramatic before/after photos tied to NAD injections alone is almost certainly conflating multiple variables. Here's the honest version by timeline.

Do not interpret this section as a promise. Individual response varies, and your outcomes depend on your baseline, protocol, lifestyle, and physician's dosing decisions.

Week 1–2 (loading phase)

Most people notice relatively little in the first week. The first sign for many is a subtle change in morning energy — not dramatic, just less dragging. Sleep quality is the second thing people commonly report noticing first. Some feel nothing until further into the loading phase; this is normal and not an indication the protocol isn't working.

Weeks 2–4 (early accumulation)

Energy levels and cognitive clarity are the most consistently reported improvements during this window. The "brain fog" reduction that patients describe is consistent with the mechanism — the brain accounts for roughly 20% of resting energy expenditure at about 2% of body mass; it's disproportionately sensitive to shifts in mitochondrial function. Exercise recovery is the other area where change becomes noticeable during this phase for athletes and high-output individuals.

Weeks 4–8 (loading course complete)

The clearest picture of your individual response forms here. Some people find a maintenance frequency of once weekly is sufficient; others need more or less. Your provider adjusts based on reported response and labs — not a fixed protocol pulled from a blog post.

What NAD injections are not:

• A substitute for sleep, resistance training, or nutrition. These aren't parallel interventions; they're the substrate the NAD+ has to work on.
• A cosmetic treatment. If you're seeing before/after photos emphasizing skin or aesthetic outcomes, those are likely driven by confounding factors.
• A single-injection fix. The cumulative model is the mechanism — repletion, not a bolus correction.

For a deeper, honest walkthrough of the week-by-week timeline — and what the evidence does and doesn't support — read what to realistically expect from NAD+ injections.

Honest answer: the mechanism is real, the reported effects are consistent with that mechanism, and the controlled human evidence is limited — particularly at the longevity endpoints the category tends to attract.

What the evidence supports:

• NAD+ declines with age across multiple tissues (reproduced across organisms and measurement methods)
• Oral NAD precursors raise blood NAD+ levels — confirmed in humans (Martens et al., 2018)
• Sirtuin activation requires NAD+ and is associated with longevity-related signaling in preclinical models
• Mitochondrial function is NAD-dependent, and mitochondrial dysfunction is a central feature of metabolic aging
• The pharmacokinetic argument for injection over oral is sound, even if the head-to-head human comparison is thin

What the evidence doesn't yet support:

• That NAD injections extend human healthspan or lifespan (not tested at scale)
• That injections produce meaningfully superior clinical outcomes versus oral precursors in controlled human trials
• That the subjective improvements reported by patients are attributable to NAD+ alone versus confounders (better protocols, lifestyle changes, placebo effect for engaged health consumers)

"Do NAD injections work" in the sense of "does the mechanism make sense and do people consistently report meaningful effects" — yes. In the sense of "is there a large, randomized, placebo-controlled trial proving specific clinical outcomes for injectable NAD+" — no. Both things are true, and the gap between them is where calibrated clinical judgment lives.

NAD injections are well-tolerated in the published literature. Over 70 published studies on NAD therapies suggest a generally favorable safety profile. The adverse event profile differs meaningfully by route.

Subcutaneous injections:

• Local injection-site irritation, mild redness or tenderness (manageable with proper technique and site rotation)
• Systemic side effects are uncommon at standard doses
• Headache and post-session fatigue have been reported rarely at higher doses

IV infusions (for comparison):

Rate-dependent reactions — flushing, mild chest pressure, nausea — are common when infusion speed is too high. Slowing the rate resolves them in virtually every case. These are not NAD side effects per se; they're rate-of-delivery effects.

What NAD injections don't do:

NAD+ does not accumulate to toxic levels — there is no established toxic dose. That said, "no known toxic dose" is not the same as "dose insensitively." What's prescribed is what's appropriate for your situation, not the maximum that exists.

Patients who need extra review before starting:

• Active malignancy — sirtuin and PARP pathways are not trivial considerations in an oncology context; discuss with your oncologist
• Pregnancy and breastfeeding — contraindicated
• Active cardiovascular conditions, history of low blood pressure or arrhythmias — flag at intake
• Current anticoagulants, antihypertensives, insulin, or chemotherapy — medication interactions exist and require a full review
• Severe hepatic or renal disease — specialist input required

We don't publish specific dosing numbers here, and neither should any responsible source — because dosing is individualized. What we can describe is the framework.

General dosing framework for subcutaneous NAD injections:

A loading phase typically involves more frequent administration (two to three times weekly for the first several weeks), followed by a maintenance phase (once weekly, or as adjusted based on your response). Common subcutaneous dose ranges in clinical protocols run from 100 mg to 200 mg per injection; IM protocols sometimes run higher. What's appropriate for you depends on your baseline metabolic picture, your goals, your labs, and your physician's clinical judgment.

What affects your dose:

• Age and estimated baseline NAD+ status
• Concurrent medications or therapies (particularly GLP-1 medications, where metabolic demand context matters)
• Reported response at each follow-up
• Biomarker tracking your provider is using

There is no universal "NAD injections dosage" that applies across patients. The prescription is the determination. That's the point.

NAD injections cost varies by provider, route, protocol length, and whether you're in a clinical or home-administration model. Here's the general landscape.

At-home subcutaneous programs (physician-prescribed, compounded, home-administered): typically range from $150–$400 per month depending on dosing frequency and the compounding pharmacy's pricing.

IV NAD infusion clinics: per-session costs typically run $200–$600+ per session; at standard loading frequencies, this adds up quickly. Many protocols involve 3–5 initial sessions followed by monthly maintenance.

Oral NAD precursor supplements (NMN/NR): $50–$150 per month at effective doses. Lower cost; more variable bioavailability.

At Protocol MD, the consultation is free and every plan's price is published up front — you see the full cost before you check out, not after. We place a hold on your card at checkout and charge it only when a physician approves. If cost is a factor (and it's always a factor), that's part of the intake conversation.

Profiles that tend to benefit

• Adults 35+ with declining energy, recovery, or cognitive sharpness who've addressed the foundational variables (sleep, training, nutrition) and want a targeted intervention
• People on GLP-1 medications — a relevant and under-discussed overlap, since GLP-1 therapy often involves rapid metabolic adaptation and the physiological demand for cellular energy substrate support is elevated during active weight change
• Athletes or high-output professionals seeking accelerated recovery where the metabolic demand is genuinely elevated
• Adults focused on healthy aging who want a physician-supervised way to support cellular energy and longevity pathways as NAD+ naturally declines

Contraindications and cautions

Active malignancy warrants careful discussion with an oncologist before starting — sirtuin and PARP pathways are not trivial biochemical considerations in that context. Pregnancy and breastfeeding are contraindications. Patients on anticoagulants, antihypertensives, insulin, or chemotherapy need a full medication review — interactions exist, and they matter. Severe hepatic or renal disease requires specialist input.

Anyone with a history of low blood pressure or arrhythmias should flag this at intake. These aren't disqualifying conditions for every patient, but they change the clinical calculus.

There is a gray market for NAD — you can find subcutaneous vials and IV bags from sellers who operate in the same unregulated space as gray-market peptides. The parallel is direct: the molecule might be exactly what the label claims. The sterility, dosing accuracy, and absence of contaminants — those are questions you're answering with trust in a seller who has no accountability structure and no license at stake.

This isn't a morality lecture. It's a quality-of-evidence argument. When you're introducing something directly into subcutaneous tissue, "probably pharmaceutical-grade" is a strange standard. One analysis found roughly 38% of online-sold peptides met basic purity standards — which is the same supply chain this market overlaps with.

At Protocol MD, NAD+ injections are compounded at a 503A-licensed pharmacy, prescribed by a US-licensed physician after a proper intake, and dosed based on your specific situation and bloodwork. That structure exists because the injection route requires it. The physicians we work with don't prescribe into the dark.

"NAD injections near me" is a high-volume search that mostly leads to IV drip clinics. Here's the thing about that model: if you're doing subcutaneous NAD injections on a home protocol, "near me" stops mattering the way it used to. If you're weighing your options, our guide to where to get NAD+ injections walks through the trade-offs.

Protocol MD operates nationally via telehealth, available to patients in all 50 U.S. states — which means your intake consultation, physician review, and prescription happen remotely, and the compounded, physician-prescribed NAD+ ships to you. The injection happens at home, once trained. No clinic visits, no IV infusion schedule, no hourly drip-lounge pricing.

Because it runs on telehealth, availability doesn't depend on a clinic near you — a physician licensed in your state reviews your intake and prescribes if it's appropriate.

In short, NAD+ injections deliver the coenzyme directly and skip the conversion steps oral supplements need, but on a well-established mechanism they still require a physician evaluation and a compounded prescription rather than self-directed dosing.